567 Stability of PASI 90 Response in Psoriasis Patients Treated With Ixekizumab or Ustekinumab

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.643
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Efficacy and Safety of Ustekinumab in Patients With Psoriasis and Psoriatic Arthritis

Clinical pharmacology and therapy
2018English

Effectiveness of Resuming Ustekinumab Therapy in Psoriasis Patients With Metabolic Disorders. Clinical Experience

Vestnik dermatologii i venerologii
2019English

Ustekinumab in Real-Life Practice: Experience in 116 Patients With Moderate-To-Severe Psoriasis

Acta Medica Portuguesa
Medicine
2019English

Characterization of Insufficient Responders to Ustekinumab in Patients With Moderate-To-Severe Psoriasis in the US Corrona Psoriasis Registry

Journal of Dermatological Treatment
Dermatology
2020English

Metabolic Parameters in Psoriatic Patients Treated With Interleukin-12/23 Blockade (Ustekinumab)

Journal of Dermatology
DermatologyMedicine
2017English

Transition to Ustekinumab in Patients With Moderate-To-Severe Psoriasis and Inadequate Response to Methotrexate: A Randomized Clinical Trial (TRANSIT)

British Journal of Dermatology
DermatologyMedicine
2014English

Toxoplasmosis in a Patient Receiving Ixekizumab for Psoriasis

JAAD Case Reports
Dermatology
2020English

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

Gastroenterology
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy